血清miR-145表达与乳腺癌患者的相关性分析(1)
摘要：目的 探讨乳腺癌骨转移患者血清miR-145的表达水平及其临床意义。方法 采集上海市建工医院于2014年8月～2017年8月收治的160例乳腺癌患者的血清样本，其中乳腺癌骨转移患者与非骨转移患者各80例。采用实时荧光定量PCR检测血清样本中miR-145的表达水平，并分析其与有无骨转移，骨转移程度、骨痛程度的相关关系。结果 骨转移患者血清中miR-145的相对表达量低于乳腺癌非骨转移患者[(1.22±0.24)vs(2.57±0.38) ]，差异有统计学意义(P<0.05);且miR-145的相对表达量与患者的骨转移程度(r=-0.873)、骨痛程度(r=-0.685)呈负相关，差异有统计学意义(P<0.05)。结论 乳腺癌骨转移患者血清miR-145的表达量明显降低，且与病情呈负相关，miR-145可作为诊断及病情评估指标。
关键词：miR-145;乳腺癌;骨转移
中图分类号：R737.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.07.002
, 百拇医药
文章编号：1006-1959(2019)07-0005-03
Abstract：Objective To investigate the expression level of serum miR-145 in patients with breast cancer and its clinical significance. Methods Serum samples of 160 breast cancer patients admitted to Shanghai Construction Engineering Hospital from August 2014 to August 2017 were collected， including 80 patients with breast cancer metastasis and non-bone metastasis. Real-time quantitative PCR was used to detect the expression level of miR-145 in serum samples， and its correlation with bone metastasis， bone metastasis and bone pain was analyzed. Results The relative expression of miR-145 in patients with bone metastases was lower than that in patients with non-bone metastases [(1.22±0.24) vs (2.57±0.38)]， the difference was statistically significant (P<0.05); and miR-145 The relative expression was negatively correlated with the degree of bone metastasis (r=-0.873) and the degree of bone pain (r=-0.685)， the difference was statistically significant (P<0.05). Conclusion The expression of serum miR-145 is significantly decreased in patients with bone metastasis from breast cancer， and it is negatively correlated with the condition. miR-145 can be used as a diagnostic and disease assessment index.
, http://www.100md.com
Key words：miR-145;Breast cancer;Bone metastasis
乳腺癌(breast cancer)是发生于乳腺上皮组织的恶性肿瘤，是目前全球女性最常见的恶性肿瘤之一，占女性肿瘤总发病率的30%[1，2]。尽管随着乳腺癌根治术技术的不断提高及各种靶向性药物的应用，乳腺癌患者的生存率及生活质量都有了显著提高，但其复发、转移仍是影响患者预后的主要因素。其中尤以骨转移最为常见，其发生率远高于肺、肝转移。有研究表明以骨转移为首发症状患者占27%～50%，乳腺癌患者术后复发性患者2年内发生骨转移的概率高达63.4%[3，4]，骨转移早期症状不典型，诊断困难，发现时多已丧失最佳治疗时机，且病情进展迅速，其5年生存率仅有20%[5]。因此，乳腺癌骨轉移的实验室生化检查有极大的临床意义，是近年来的研究热点。微小RNA(miR)是一类高度保守的由18～22个核苷酸组成的单链非编码RNA。其经由Dicer酶完成miR前体到成熟体的转化[6，7]。miR通过结合于mRNA的3'末端的非编码区从而抑制靶mRNA的翻译发挥调控靶基因表达的作用[8]。差异性表达的mRNA广泛参与肿瘤的发生、发展，因此特异性表达mRNA也被认为是肿瘤诊断、治疗的新靶点。本研究探讨了miR-145在乳腺癌骨转移患者的表达量，以期为乳腺癌骨转移的诊断及治疗靶点的筛查提供新的思路。, http://www.100md.com(卜易莹 韩东兴 刘邦令)
关键词：miR-145;乳腺癌;骨转移
中图分类号：R737.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.07.002
, 百拇医药
文章编号：1006-1959(2019)07-0005-03
Abstract：Objective To investigate the expression level of serum miR-145 in patients with breast cancer and its clinical significance. Methods Serum samples of 160 breast cancer patients admitted to Shanghai Construction Engineering Hospital from August 2014 to August 2017 were collected， including 80 patients with breast cancer metastasis and non-bone metastasis. Real-time quantitative PCR was used to detect the expression level of miR-145 in serum samples， and its correlation with bone metastasis， bone metastasis and bone pain was analyzed. Results The relative expression of miR-145 in patients with bone metastases was lower than that in patients with non-bone metastases [(1.22±0.24) vs (2.57±0.38)]， the difference was statistically significant (P<0.05); and miR-145 The relative expression was negatively correlated with the degree of bone metastasis (r=-0.873) and the degree of bone pain (r=-0.685)， the difference was statistically significant (P<0.05). Conclusion The expression of serum miR-145 is significantly decreased in patients with bone metastasis from breast cancer， and it is negatively correlated with the condition. miR-145 can be used as a diagnostic and disease assessment index.
, http://www.100md.com
Key words：miR-145;Breast cancer;Bone metastasis
乳腺癌(breast cancer)是发生于乳腺上皮组织的恶性肿瘤，是目前全球女性最常见的恶性肿瘤之一，占女性肿瘤总发病率的30%[1，2]。尽管随着乳腺癌根治术技术的不断提高及各种靶向性药物的应用，乳腺癌患者的生存率及生活质量都有了显著提高，但其复发、转移仍是影响患者预后的主要因素。其中尤以骨转移最为常见，其发生率远高于肺、肝转移。有研究表明以骨转移为首发症状患者占27%～50%，乳腺癌患者术后复发性患者2年内发生骨转移的概率高达63.4%[3，4]，骨转移早期症状不典型，诊断困难，发现时多已丧失最佳治疗时机，且病情进展迅速，其5年生存率仅有20%[5]。因此，乳腺癌骨轉移的实验室生化检查有极大的临床意义，是近年来的研究热点。微小RNA(miR)是一类高度保守的由18～22个核苷酸组成的单链非编码RNA。其经由Dicer酶完成miR前体到成熟体的转化[6，7]。miR通过结合于mRNA的3'末端的非编码区从而抑制靶mRNA的翻译发挥调控靶基因表达的作用[8]。差异性表达的mRNA广泛参与肿瘤的发生、发展，因此特异性表达mRNA也被认为是肿瘤诊断、治疗的新靶点。本研究探讨了miR-145在乳腺癌骨转移患者的表达量，以期为乳腺癌骨转移的诊断及治疗靶点的筛查提供新的思路。, http://www.100md.com(卜易莹 韩东兴 刘邦令)